Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05571410 · ClinicalTrials.gov registry record · NA

BP PAL - Hypertension Chat Bot Pilot

A NA study, sponsored by University of Pennsylvania.

Completed
Registry status
NA
Development phase
300
Enrollment target

NCT05571410: Completed NA study, sponsored by University of Pennsylvania.

NCT05571410 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 300 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05571410, a NA study, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
NA
Development phase
300 participants
Enrollment target

Study Summary

A 2-arm randomized pilot trial aimed at evaluating the effectiveness of a 6-month remote monitoring program for the management of hypertension (HTN). 300 eligible patients will be randomized in a 1:1 ratio into two recruitment arms: A) Control (usual care), or B) Remote monitoring via automated messaging program. The target population are patients at the Penn Family Medicine University City and Westtown primary care practices with baseline poor blood pressure control as indicated by two blood pressures greater than 140/90 within the past twelve month including the most recent measurement and on at least one anti-hypertensive agent.

Primary Outcome

change in systolic blood pressure from baseline to 6 month visit

Interventions

  • BEHAVIORAL HTN Chat bot

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2023-01-09
Est. Completion 2023-10-31
Phase NA
University of Pennsylvania

1,423 total trials

What the finished NCT05571410 record still lists

NCT05571410 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).

The record links to 0 conditions, and to 1 intervention - of which HTN Chat bot is the first listed.

NCT05571410 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05571410 about?

NCT05571410 is a clinical study titled "BP PAL - Hypertension Chat Bot Pilot". A 2-arm randomized pilot trial aimed at evaluating the effectiveness of a 6-month remote monitoring program for the management of hypertension (HTN). 300 eligible patients will be randomized in a 1:1 ratio into two recruitment arms: A) Control (usual care), or B) Remote monitoring via automated mess...

What is the current status of trial NCT05571410?

This trial is currently completed. It is a NA study. The enrollment target is 300 participants. The study started on 2023-01-09. Estimated completion is 2023-10-31.

What interventions are being tested in trial NCT05571410?

The interventions under investigation include: HTN Chat bot (BEHAVIORAL).

Who is sponsoring clinical trial NCT05571410?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05571410's enrollment target sits among peer trials

300 330th of 2000 higher than 1,630 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05571410, the US trial registry maintained by the National Library of Medicine. NCT05571410 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.